Skip to market wire
Back to Market返回行情

TEVA Teva Pharmaceutical Industries Limited

USHealthcare
$36.65+0.08%OpenMarket Cap: $42.68B

As of 2026-09-04 11:19

Why TEVA matters now

Teva Pharmaceutical Industries Limited (TEVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $36.65 with +0.08% on the session and $42.68B in market capitalization; recent performance reads 1-month -7.60% and YTD +0.87%.

The latest financial table shown here is Q1 2026, with revenue of $3.98B, net income of $369.0M, and EPS of $0.31. Investors can compare that operating picture with valuation signals such as P/E 24.24 and FCF yield 5.1%.

InvestLog's latest related AI research is a Rating Change note titled "UBS raises TEVA target to $48". The latest indexable market news headline is "Outperforming Pharma Stock Still Has Upside Potential" from Schaeffers Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes Kalif Eliyahu Sharon filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

24.24

PEG

0.13

P/B

4.44

P/S

2.13

EV/EBITDA

15.20

DCF Value

$21.73

FCF Yield

5.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

52.0%

Operating Margin

19.4%

Net Margin

9.0%

ROE

20.8%

ROA

3.9%

ROIC

11.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$3.98B$369.0M$0.31
Q4 2025$4.71B$480.0M$0.41
FY 2025$17.26B$1.41B$1.20
Q3 2025$4.48B$433.0M$0.37

Analyst Ratings

Consensus

Buy

Target (Consensus)

$40.00

Target (Median)

$40.00

Target Range

$36.00 - $42.00

Strong Buy: 5Buy: 8Hold: 0Sell: 0Strong Sell: 0
BarclaysOverweight
2026-05-06
Truist SecuritiesBuy
2026-04-30
UBSBuy
2026-04-30
JP MorganOverweight
2026-04-30
Piper SandlerOverweight
2026-04-30

Trading Activity

Insider Trades

Kalif Eliyahu Sharonofficer: EVP, Chief Financial Officer
Sell2026-06-16
Francis Richard Dofficer: President and CEO
Sell2026-06-08
Francis Richard Dofficer: President and CEO
Sell2026-06-08
Francis Richard Dofficer: President and CEO
Sell2026-06-08
MIGNONE ROBERTOdirector
Sell2026-06-08

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

IL

Exchange

Beta

0.85

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.